Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics completes $700 million convertible notes offering due 2029

Neutral Impact 4 of 5 financing Written later

Haemonetics completed the issuance of $700 million of 2.50% convertible senior notes due June 1, 2029 on May 28, 2024, including $100 million from the full exercise of the initial purchasers' option. The company used the proceeds to pay $88.2 million for capped call transactions, repurchase $200.0 million of its 0.00% convertible notes due 2026 for $185.5 million in cash, and repay the $230.0 million revolving credit balance in full.

Key points

  • $700 million of 2.50% convertible senior notes due June 1, 2029, issued May 28, 2024
  • Initial conversion price of about $117.12 per share; capped call cap price initially $180.18
  • Proceeds: $88.2 million for capped calls, $185.5 million to repurchase $200.0 million of 2026 notes, $230.0 million revolver repaid
  • Notes are senior unsecured obligations; interest payable semi-annually beginning December 1, 2024

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECMay 29, 2024, 4:06 PM ET
Accession number0001104659-24-066056

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 29, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.